Genetic risk factors for CVD
Atherosclerosis and venous thrombosis are two major manifestations of CVD. Both can be caused by complex interactions of environmental and genetic factors. An unhealthy lifestyle in combination with genetic risk factors can contribute to the occurrence of CVD. Similarly, a combination of adverse influences (female hormone intake, immobilization, surgery or cancer) and variations in genes responsible for the coagulation system can contribute to CVD. Testing for genetic risk factors can therefore be a powerful tool for guidance to a lifestyle that is in accordance with an individual’s genetic predisposition.
The Devyser CVD kit offers a very simple procedure for identification of mutations and polymorphisms implicated as genetic risk factors for the development of CVD. It is a multiplex PCR reagent kit for simultaneous detection of seven genetic risk factors associated with CVD:
- Factor XIII (F13A1)
The V34L variant plays a protective role against venous thrombosis. It has also been associated with lower risk for stroke and myocardial infarction.
- Fibrinogen Beta Chain (FGB)
The -455G>A polymorphism in the promoter region of the FGB gene is associated with elevated plasma fibrinogen levels, an independent predictor of coronary heart disease.
- Human Platelet Antigen 1 (HPA1b)/Platelet receptor GPIIIa/(ITGB3)
HPA1b is associated with an increased risk of myocardial infarction and stroke.
- Angiotensin Converting Enzyme (ACE)
The 287bp gene deletion/insertion polymorphism is associated with an increased risk for hypertension and for myocardial infarction in elderly patients and smokers.
- Angiotensin/ Angiotensinogen (AGT)
The M268T polymorphism has been associated with an increased risk of hypertension.
- Angiotensin II type 1 receptor (AGTR1)
The 1166A>C (c.*86A>C) polymorphism is associated with an increased risk for hypertension and CVD.
- Cystathionine Beta-Synthase (CBS)
The 844ins68 variant has been associated with an increased risk of premature occlusive arterial disease.